# A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

> **NCT01791244** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 93 (actual)

## Conditions studied

- Multiple Sclerosis
- Relapsing-Remitting

## Interventions

- **DRUG:** Rebif®

## Key facts

- **NCT ID:** NCT01791244
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-02-29
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2017-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791244, "A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01791244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*